Dr. @ZeidanMd presenting at #ASTRO26 on omitting axillary staging as part of de-escalating therapy for select patients with early-stage breast cancer. @ASTRO_org

Surgery or 5 sessions of radiation? For the first time, we have randomised head-to-head efficacy data. 🔥 #PACE_A at #ASTRO26 shows comparable 8-year cancer control, and nearly half of surgical patients still use pads at 5 years. LBA 32 - EFFICACY OF RADICAL PROSTATECTOMY VERSUS STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR LOCALISED PROSTATE CANCER: RESULTS FROM AN INTERNATIONAL PHASE III RANDOMISED CONTROLLED TRIAL (PACE - A) PACE-A (phase III) randomised 123 men with localised #ProstateCancer to 5-fraction SBRT☢️ (36.25 Gy) or prostatectomy, without ADT. ➡️At 8 years' median follow-up, biochemical/clinical failure-free rates were 91.2% vs 83.7% (HR 0.48; p=0.18), with 94.8% vs 94.1% at 5 years. ➡️Pad use at 5 years: 8.3% SBRT vs 48% surgery. Grade ≥2 toxicity was low in both arms. ✅SBRT offers comparable long-term cancer control with far better urinary continence. @nickva1, @alison_tree, @EmmaHall71, @ICR_CTSU, @ICR_London, @royalmarsdenNHS @OncoALert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Prostatectomy vs radiation. Both excellent options with #prostatecancer. Trend in treated patients is similar number of men choosing organ preservation and surgery. #radonc #ASTRO26 #pcsm

Low-dose radiation shows lasting benefits in patients with knee osteoarthritis news-medical.net/news/202609…

2 crucial questions a #prostate cancer patient should ask their Urologist: 1. How many radical prostatectomies have you done? (Surgical learning curves show very high +ve margin & complication rates initially) 2. Can I speak to a radiation oncologist? #PCSM #ASTRO26 #PACEA

#ASTRO26 Plenary Discussant @DeborahCitrin Putting PACE-A into perspective PACE-B validates SBRT --> GU005 refines the picture --> PACE-A extends the comparison to RP

I treat cancer, not pickles 🥒 GTV >> DIL for #ProstateCancer #radonc #ASTRO26 @ASTRO_org

#ASTRO26 @nickva1 presents 5 yr data of PACE-A: SBRT v RP no differences in clinical outcomes use of =1 urinary pad 8.3% SBRT V 48% RP Low GI/GU events <%4 each arms

What else do we need to declare SBRT a standard of care for low & intermediate-risk #ProstateCancer? 8-yr #ASTRO26 results: • SBRT matches surgery in disease control • Numerically favors SBRT in BCF-free rates • Excellent safety profile Time to shift practice?

Safety and efficacy of stereotactic body radiotherapy for localized renal pelvic and ureteral carcinoma. Presented by Xiaoying Li, MD. #ASTRO26 written coverage by @chavarriagaj > bit.ly/4xPpmnc @ASTRO_org

#ASTRO26 @ASTRO_org Day 2 selfie 7 @Antoniojconde 🇪🇸 @banu_atalar 🇹🇷 #TROD For many more km!!

Presented our @ARRO_org-jDEGRO survey at #ASTRO26: only 20% of U.S. trainees had rotation exposure to nonmalignant RT, and 65% saw just 0-10 cases during residency. Yet 95.8% supported including training for non malignant RT in core residency training. #RadOnc #MedEd @ASTRO_org

☢️ #ASTRO26: LDRT in knee OA is fascinating. 292 patients | 4.5 Gy/10 fractions At 3 years: 🦵 VAS pain: 21 vs 55 📈 Responders: 69% vs 25% (p<0.0001) Long-term: disability 14% vs 25%; KL-2 knee replacement 14% vs 36% (HR 0.32, p=0.021).

Can we safely make salvage RT shorter? ☢️✂️ @RadOncUH’s @kendallngarrett presents our experience with 55 Gy/20 fx vs 66 Gy/33 fx after prostatectomy: comparable early disease control and GU/GI toxicity. 13 fewer trips to radiation. Same early outcomes. #ASTRO2026

Clinical trials session packed for some amazing trial data including long term clinical and functional outcomes for LDRT for knee osteoarthritis. Great work coordinating the publication of this data @KoneruMd ! #ASTRO2026

Me han pasado este video de la comunicación que hace una médica de Ceuta en el congreso de oftalmología que ha tenido lugar estos días en Palma. En 5 min explica lo que ha pasado en Ceuta y cómo están. Impresio mucho. @SEOCongreso

Initial Results of NRG Oncology NRG-GI003: A Phase III Randomized Trial of Protons vs. Photons for HCC #ASTRO2026 Conclusion: Proton therapy did not improve OS, PFS, LP, or AEs in patients with advanced HCC. Clinical Trial Number: NCT03186898.

Patients are being harmed and dying because the NHS is replacing doctors with nurses and other healthcare workers, medics have warned. 🔗:telegraph.co.uk/news/2026/09…

📌 Phase I study of stereotactic ablative radiotherapy (SABR) in inoperable breast cancer 🔗 thebreastonline.com/article/… @OncoAlert #OncoAlertAF @TheBreastOnline @Monthy_A 👉 Single-center, single-arm, phase I study 👉 10 patients (11 tumors), median age 91 years 👉 ≥70 years with unifocal T1-2N0 M0-1 breast cancer, inoperable or refusing surgery ☢️ SABR in 5 fractions: 36 Gy → 38 Gy → 40 Gy Primary endpoint: ≥Grade 3 adverse events within 6 months Secondary endpoints: LC, PFS, OS 24m 🔹 No dose-limiting or acute adverse events 🔹 Only one late G1 subcutaneous fibrosis 🔹 At 24 months: LC 100% | PFS 90% | OS 90% ◼️ Definitive SABR up to 40 Gy in 5 fractions was safe and well tolerated in this small cohort of elderly/frail patients, with promising preliminary disease control. ➡️ Further evaluation in phase II studies is warranted.

Could “more bladder filling” actually make prostate radiotherapy harder for both patients and treatment teams?🎯 practicalradonc.org/article/… Excessive Bladder Filling at Simulation Correlates with Longer Treatment Times, More Interruptions, and Inferior Patient Experiences During #ProstateCancer Radiotherapy☢️ This study examined whether excessive bladder filling during prostate radiotherapy affects treatment efficiency and patient experience. ➡️Among 211 patients, bladder diameters >10 cm were associated with longer treatment times, more table interruptions, increased worry, and greater frustration. ➡️Importantly, coaching patients to reduce bladder size was feasible and successfully achieved in all 20 coached patients, resulting in shorter treatment times. ✅The findings support personalized bladder-filling guidance during prostate radiotherapy. @ASarafMD2, @jonathan_leeman, @DrPaulNguyen, @MoningiShalini @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists